ZVIA vs. VTVT, SLS, CGTX, SHLT, DTIL, TIL, IFRX, ANEB, STIM, and RVPH
Should you be buying Zevia PBC stock or one of its competitors? The main competitors of Zevia PBC include vTv Therapeutics (VTVT), SELLAS Life Sciences Group (SLS), Cognition Therapeutics (CGTX), SHL Telemedicine (SHLT), Precision BioSciences (DTIL), Instil Bio (TIL), InflaRx (IFRX), Anebulo Pharmaceuticals (ANEB), Neuronetics (STIM), and Reviva Pharmaceuticals (RVPH). These companies are all part of the "medical" sector.
vTv Therapeutics (NASDAQ:VTVT) and Zevia PBC (NYSE:ZVIA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, community ranking, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.
Zevia PBC has a consensus target price of $3.21, indicating a potential upside of 214.54%. Given vTv Therapeutics' higher probable upside, analysts clearly believe Zevia PBC is more favorable than vTv Therapeutics.
vTv Therapeutics received 336 more outperform votes than Zevia PBC when rated by MarketBeat users. Likewise, 57.73% of users gave vTv Therapeutics an outperform vote while only 31.91% of users gave Zevia PBC an outperform vote.
vTv Therapeutics has higher earnings, but lower revenue than Zevia PBC. vTv Therapeutics is trading at a lower price-to-earnings ratio than Zevia PBC, indicating that it is currently the more affordable of the two stocks.
In the previous week, Zevia PBC had 19 more articles in the media than vTv Therapeutics. MarketBeat recorded 24 mentions for Zevia PBC and 5 mentions for vTv Therapeutics. Zevia PBC's average media sentiment score of 0.65 beat vTv Therapeutics' score of -0.11 indicating that vTv Therapeutics is being referred to more favorably in the media.
17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 53.2% of Zevia PBC shares are held by institutional investors. 1.7% of vTv Therapeutics shares are held by insiders. Comparatively, 12.6% of Zevia PBC shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
vTv Therapeutics has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Zevia PBC has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.
vTv Therapeutics has a net margin of 0.00% compared to vTv Therapeutics' net margin of -15.58%. Zevia PBC's return on equity of 0.00% beat vTv Therapeutics' return on equity.
Summary
Zevia PBC beats vTv Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Zevia PBC News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZVIA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZVIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Zevia PBC Competitors List
Related Companies and Tools